| Autor: |
Cloutier, Alexandre, Marois, Isabelle, Cloutier, Diane, Verreault, Catherine, Cantin, Andr&eaute; M., Richter, Martin V. |
| Předmět: |
|
| Zdroj: |
Journal of Infectious Diseases; 2/15/2012, Vol. 205 Issue 4, p621-630, 10p |
| Abstrakt: |
Background. Growing evidence indicates that influenza pathogenicity relates to altered immune responses and hypercytokinemia. Therefore, dampening the excessive inflammatory response induced after infection might reduce influenza morbidity and mortality. Methods. Considering this, we investigated the effect of the anti-inflammatory molecule 15-deoxy-▵12,14- prostaglandin J2 (15d-PGJ2) in a mouse model of lethal influenza infection. Results. Administration of 15d-PGJ2 on day 1 after infection, but not on day 0, protected 79% of mice against lethal influenza infection. In addition, this treatment considerably reduced the morbidity associated with severe influenza infection. Our results also showed that treatment with 15d-PGJ2 decreased influenza-induced lung inflammation, as shown by the diminished gene expression of several proinflammatory cytokines and chemokines. Unexpectedly, 15d-PGJ2 also markedly reduced the viral load in the lungs of infected mice. This could be attributed to maintained type I interferon gene expression levels after treatment. Interestingly, pretreatment of mice with a peroxisome proliferator-activated receptor gamma (PPARγ) antagonist before 15d-PGJ2 administration completely abrogated its protective effect against influenza infection. Conclusions. Our results demonstrate for the first time that treatment of mice with 15d-PGJ2 reduces influenza morbidity and mortality through activation of the PPARγ pathway. PPARγ agonists could thus represent a potential therapeutic avenue for influenza infections. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
